This study aimed to use network meta-analysis to compare the efficacy and safety of CDK4/6 inhibitors combined with ET, providing a more evidence-based foundation for clinical drug selection in patients with HR+/HER2-breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.